Danaher Corp (DHR)
Health Care · Life Sciences Tools & Services · US stock · S&P 500 component
$229.04
▼ -2.46 (1.06%)
Fair valueOvervalued
$118 −48.5% to fair value
$59fair band $83–$153$177
Day's range
$228.36 – $231.93
52-week range
$160.31 – $241.35
About Danaher Corp
Tools for life sciences research, diagnostics and biopharmaceutical production come from Danaher, a science and technology company. Its businesses include Cytiva, which supplies bioprocessing equipment, Beckman Coulter and Cepheid in diagnostics, and Leica Microsystems and SCIEX in research instruments. Customers include biopharma manufacturers, hospitals, clinical laboratories and universities. The company is organised into biotechnology, life sciences and diagnostics groups.
Revenue of $25.1 billion over the last twelve months comes from instruments, recurring consumables and reagents, and service. Revenue has changed at -2.7% a year across the last three years. The operating margin is 20.4%, the business earns 6% on the capital invested in it, and net debt is 4.6 times EBITDA. The dividend yield is 0.7%. On the site's X-Ray Score it receives 28 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $160.31 – $241.35Volume 3,516,096Daily, split-adjusted
Vitals
Market cap$162.1B
52-week range$160.31 – $241.35
Volume (last day)3,516,096
P/E (TTM)40.7
EBIT / EV yield2.8%
Free-cash-flow yield3.4%
Dividend yield0.7%
Revenue (TTM)$25.1B
Net income (TTM)$4.0B
Operating margin20.4%
Return on capital5.6%
Debt incl. leases$27.9B
Cash & securities$4.3B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$118model spread $113 – $123
Overvalued
−48.5% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $229
Undervalued < $83Fair $83 – $153Overvalued > $153
10-year DCF (market-scaled)
$70
Peer multiples
$153
Earnings power floor (not blended)
$47
Fundamentals-adjusted multiple
$131
Growth the price implies
25.0%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
22/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield2.8%
Free-cash-flow yield3.4%
Fair value vs price0.5×
Growth
Weak
14/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)-2.7%
EPS growth (3y)-19.4%
Growth consistency70%
Profitability
Weak
34/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital5.6%
Operating margin20.4%
Gross profitability15.9%
Financial health
Weak
40/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA4.6×
Interest cover17.6×
Dividends
Weak
37/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.7%
Dividends vs free cash flow20%
Dividend growth2.4%
Quarterly results: last 6 quarters
-0.9%
Mar '25
+3.4%
Jun '25
+4.4%
Sep '25
+4.6%
Dec '25
+3.7%
Mar '26
+5.5%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $6.3B, diluted EPS $1.23.
Compare with peers
MTD Mettler Toledo Interna...50 A Agilent Technologies,...42 IQV Iqvia Holdings Inc.42 TECH BIO-TECHNE Corp40Other Life Sciences Tools & Services companies by X-Ray Score.
Fundamentals checklist
● 0 Good · ● 5 Average · ● 11 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldBad
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioAverage
Net debt / EBITDABad
Interest coverAverage
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginAverage
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 28/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $24.8B | $26.6B | $23.9B | $23.9B | $24.6B |
| Operating income | $6.4B | $7.5B | $5.2B | $4.9B | $4.7B |
| Net income | $6.4B | $7.2B | $4.8B | $3.9B | $3.6B |
| Operating cash flow | $8.4B | $8.5B | $7.2B | $6.7B | $6.4B |
| Operating margin | 25.7% | 28.3% | 21.8% | 20.4% | 19.1% |
| Free cash flow | $7.1B | $7.4B | $5.8B | $5.3B | $5.3B |
| Diluted EPS | $8.61 | $9.66 | $6.38 | $5.29 | $5.05 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
6 bullish · 1 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 222.2 | Bullish |
| EMA 10 | 223.7 | Bullish |
| SMA 20 | 221.3 | Bullish |
| EMA 20 | 220.5 | Bullish |
| SMA 50 | 213.6 | Bullish |
| EMA 50 | 213.4 | Bullish |
| SMA 100 | 201.4 | Bullish |
| EMA 100 | 206.5 | Bullish |
| SMA 200 | 200.6 | Bullish |
| EMA 200 | 203.5 | Bullish |
Oscillators (daily)
| RSI (14) | 62.69 | Neutral |
| MACD (12, 26) | 4.03 | Bullish |
| Momentum (12) | 3.38 | Bullish |
| Stochastic %K (14) | 81.78 | Bearish |
| Williams %R (14) | -18.22 | Bearish |
| CCI (20) | 153.7 | Bearish |
Pivot points (classic, last session)
S3 224.1 | S2 226.2 | S1 227.6 | Pivot 229.8 | R1 231.2 | R2 233.3 | R3 234.8 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
1.52 USD
Yield on today's price
0.66%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 30 Sep 2026 | 0.4000 |
| 26 Jun 2026 | 0.4000 |
| 27 Mar 2026 | 0.4000 |
| 26 Dec 2025 | 0.3200 |
| 26 Sep 2025 | 0.3200 |
| 27 Jun 2025 | 0.3200 |
| 28 Mar 2025 | 0.3200 |
| 27 Dec 2024 | 0.2700 |
| 27 Sep 2024 | 0.2700 |
| 28 Jun 2024 | 0.2700 |
| 27 Mar 2024 | 0.2700 |
| 28 Dec 2023 | 0.2400 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
DHR SEC filings
13 Oct 2026
8-KSEC EDGAR
Director or officer change; Other events
3 Aug 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
21 Jul 2026
8-KSEC EDGAR
Results of operations
21 Jul 2026
10-QSEC EDGAR
Quarterly report
3 Jun 2026
8-KSEC EDGAR
Other events
7 May 2026
8-KSEC EDGAR
Director or officer change; Shareholder vote results
29 Apr 2026
8-KSEC EDGAR
Entered a material agreement; Other events
23 Apr 2026
424B5SEC EDGAR
424B5
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.